Treasury Wine Estates has won a nearly $352,000 judgment against an Australian company for allegedly violating its trade marks by making and selling copycat Penfolds products in China and Australia.
Former Tennis Australia director Harold Mitchell has denied allegations by the Australian Securities and Investments Commission that he breached his duties when awarding broadcasting rights for the Australian Open and other tournaments to the Seven Network in 2013.
Private training company Ashley Services and auditors Deloitte and Grant Thornton will pay a combined $14.6 million to settle a shareholder class action, and IMF Bentham says it may bank $7.2 million for funding the litigation.
German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
The head of Herbert Smith Freehills’ Australian international arbitration practice has become the first female to lead the Australian Centre for International Commercial Arbitration.
ANZ has reached an in-principle settlement in two class actions alleging it breached its responsible lending obligations by providing loans to purchasers of 7-Eleven franchises that were not financially viable.
Funding for a shareholder class action against mineral sands company Iluka Resources is in doubt after Harbour Litigation Funding unilaterally backed out of an agreement to finance the litigation.
Charges in the criminal cartel case against ANZ, Citigroup and Deutsche Bank over a $2.5 billion ANZ institutional share placement have yet to be finalised, almost a year after the proceeding was filed.
The US International Trade Commission has opened an investigation into alleged patent infringement by solar companies JinkoSolar, LONGi Solar and REC Group, after Korean solar company Hanwha Q CELLS filed two related proceedings in Australian court alleging the companies are infringing its solar technology.
Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.